8.54
+0(+0.00%)
Currency In USD
| Previous Close | 8.54 |
| Open | 8.54 |
| Day High | 8.54 |
| Day Low | 8.54 |
| 52-Week High | 8.55 |
| 52-Week Low | 0.75 |
| Volume | 2.55M |
| Average Volume | 4.05M |
| Market Cap | 801.08M |
| PE | -8.63 |
| EPS | -0.99 |
| Moving Average 50 Days | 6.67 |
| Moving Average 200 Days | 2.75 |
| Change | 0 |
If you invested $1000 in Chimerix, Inc. (CMRX) 10 years ago, it would be worth $181.62 as of July 03, 2025 at a share price of $8.54. Whereas If you bought $1000 worth of Chimerix, Inc. (CMRX) shares 5 years ago, it would be worth $2,660.44 as of July 03, 2025 at a share price of $8.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
GlobeNewswire Inc.
Mar 05, 2025 12:00 PM GMT
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
GlobeNewswire Inc.
Feb 18, 2025 12:00 PM GMT
Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- C
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
GlobeNewswire Inc.
Jan 29, 2025 9:15 PM GMT
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mi
Data not available